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Abstract
Herpesviruses encode miRNAs that target both virus and host genes; however their role in herpesvirus biology is still poorly
understood. We previously identified thirty five miRNAs encoded by OvHV-2; the causative agent of malignant catarrhal fever
(MCF) and are investigating the role of these miRNAs in regulating expression of OvHV-2 genes that play important roles in
virus biology. Analysis, using RNAHybrid predicted that twoOvHV-2 encodedmiRNAs, ovhv2-miR-17-10 and ovhv2-miR-61-
1, target transcripts coding for the OvHV-2 bZIP protein Ov2. In other herpesvirus bZIP proteins are known to play important
roles in lytic virus replication. Here we show by Flow cytometry and western blotting that ovhv2-miR-17-10 and ovhv2-miR-61-
1, reduce the expression of Ov2 protein. The predicted target sites for both miRNAs within the Ov2 gene were disrupted whilst
retaining the Ov2 coding sequence. Mutation of the ovhv2-miR-61-1 target sequence restored Ov2 protein expression levels to
control levels confirming the identity of its target site. However, it was not possible to determine the binding site of ovhv2-miR-
17-10 possibly due to potential G:U pairing introduced during the mutation process. The targeting of Ov2 by two virus-encoded
miRNAs suggests an important regulatory role for Ov2 in OvHV-2 replication or reactivation.
Keywords Ovine herpesvirus-2 . Virus encodedmiRNAs, Ov2
Introduction
Malignant catarrhal fever (MCF) is a usually fatal disease of
cattle, deer, bison and other ruminants caused by viruses in the
genus Macavirus of the subfamily Gammaherpesvirinae
(McGeoch et al. 2006). MCF is characterised by sudden onset
of fever followed by lymphadenopathy, leucocytosis, severe
congestion and necrosis and erosion of the oral, conjunctival
and nasal muscosæ (Russell et al. 2009). The major causative
agents of MCF are ovine herpesvirus 2 (OvHV-2) and
alcelaphine herpesvirus 1 (AlHV-1), which cause the sheep
associated (SA-MCF) and the wildebeest associated (WA-
MCF) forms of the disease, respectively. In the case of both
the SA and WA- forms of MCF, reactivation of the virus from
latency results in the production of infectious virions that can
be transmitted to susceptible species, such as cattle, bison, or
deer found in close proximity to asymptomatically shedding
carrier animals.
Reactivation of gammaherpesviruses from their latent state
requires the expression of viral transactivators, such as the
Replication and Transcriptional Activator protein (RTA), that
promote virus replication by triggering expression of a cas-
cade of proteins that are required for viral genomic replication
and particle formation (Damania et al. 2004). The Ov2 gene of
OvHv-2 encodes a protein with a basic leucine zipper (bZIP)
domain. Herpesvirus proteins with bZIP domains include
BZLF1 of Epstein Barr Virus (EBV) (Murata 2014), and the
K8 protein of Kaposi’s sarcoma-associated herpesvirus
(KSHV) (Lefort and Flamand 2009). BZLF and K8 play im-
portant roles in the lifecycles of EBVand KSHV by modulat-
ing the activity of RTA (Liao et al. 2003; Murata 2014).
MicroRNAs (miRNAs) are short, non-coding RNAs that
regulate gene expression at a post-transcriptional level.
miRNA-mediated regulation of expression is by binding of
the seed sequence (usually nucleotides 2 to 8) to complemen-
tary sequences in the target mRNA and directing these targets
for degradation or translational silencing, depending on the
degree of complementarity observed (Bartel 2009).
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MicroRNAs have been identified in the genomes of many
virus families, though, it is the Herpesviridae, with over 300
viral microRNAs identified so far amongst its members, that
seem to have evolved tomake the greatest use of miRNAs as a
mechanism to effectively regulate cellular and virus gene ex-
pression (Grundhoff and Sullivan 2011). Independent re-
search into the targets of the miRNAs encoded by herpesvi-
ruses have identified in the genomes of viruses classified with-
in all herpesvirus sub-families, the presence of miRNAs
which target the viral transactivators (Bellare and Ganem
2009; Grey et al. 2007; Umbach et al. 2008). This is indicative
of a familial level mechanism regulating the balance between
herpesvirus lytic and latent replication cycles.
Previously our group has shown that OvHV-2 encodes for
at least thirty-five miRNAs, and that the targets of these
miRNAs include transcripts encoding the OvHV-2 RTA
(encoded by the ORF50 transcript) (reactivation) and
ORF73 (maintenance of latency) (Nightingale et al. 2014;
Riaz et al. 2014). Further analysis, using RNAHybrid
(Rehmsmeier et al. 2004) predicted that two further OvHV-2
encoded miRNAs, ovhv2-miR-17-10 and ovhv2-miR-61-1,
would target transcripts coding for the OvHV-2 protein Ov2.
In this paper, we show that two of the thirty-five identified
OvHV-2-encoded miRNAs, ovhv2-miR-17-10 and ovhv2-
miR-61-1, target the virus-encoded protein Ov2.
Furthermore, the fact that two virus-encoded miRNAs target
Ov2 is suggestive of an important regulatory role for Ov2 in
the process of OvHV-2 reactivation.
Methods
Cell culture
BJ1035 cells, an immortalized bovine T cell line from an
animal naturally-infected with OvHV-2 [3], was grown in sus-
pension culture in Iscove’s Modified Dulbecco’s Medium
(Invitrogen, UK) supplemented with 10% (v/v) foetal calf se-
rum (FCS, Sera Laboratories International, UK), 1% (v/v)
penicillin-streptomycin (Invitrogen), 20 U/ml interleukin 2
(Novartis Pharmaceuticals UK) and incubated at 37 °C, 5%
CO2. Human embryonic kidney cells (HEK-293 T) were cul-
tured in Dulbecco’sModified EagleMedium (Invitrogen) sup-
plemented with 10% (v/v) FCS and 1% (v/v) penicillin-
streptomycin-glutamine (Invitrogen) and incubated at 37 °C,
5% CO2.
Target identification
The nucleotide sequence of Ov2 was derived from the OvHv-
2 genome (Genbank accession: AY839756.1). Sequences and
position of the OvHV-2-encoded miRNA in the OvHV-2 ge-
nome have been described previously (Nightingale et al.
2014). RNAHybrid (Rehmsmeier et al. 2004) was used to
predict OvHV-2-encoded miRNA target sites within the cod-
ing region of Ov2. No G:U pairing in the seed sequence was
allowed, and a helix constraint of nucleotides 2 to 8 was used.
Primer design and cloning
The OvHV-2 OV2 gene sequence amplified by PCR from
DNA extracted from OvHV-2 positive BJ1035 cells (Schock
et al. 1998) using the DNA Blood and Tissue kit (Qiagen,
UK). The reaction contained 1 unit HotStarTaq Plus DNA
polymerase (Qiagen), 50 ng BJ1035 DNA, 200 μM dNTPS
and 8 pmols of each primer in a final reaction volume of 20μl.
The cycling conditions used for amplification were an ini-
tial denaturation step of 5 min at 95 °C, followed by 30 cycles
of 95 °C for 30 s, 58 °C for 1 min and 72 °C for 1 min, with a
final extension of 72 °C for 7 min.
Untagged Ov2 was cloned into pcDNA3.1(+) using
the restriction enzymes BamH1 and EcoR1. Ov2 was
cloned in frame with EGFP, in the vector pEGFPN1,
using the restriction enzymes Bgl II and EcoR1.
Sequencing by GATC (Cologne, Germany) confirmed
the absence of any additional mutations in the Ov2
sequence.
Site directed mutagenesis
Site-directed mutagenesis PCR was carried out using the
QuikChange Lightning Site-Directed Mutagenesis Kit
(Agilent Technologies, UK) according to the manufacturer’s
protocol. Mutagenesis primers (Table 1) were designed using
the QuikChange Primer Design Program (www.agilent.com/
genomics/qcpd). All mutations were confirmed by sequencing
by GATC.
Flow cytometry
Ten ng plasmid DNA and 100 nM miRNA mimic
(Nightingale et al. 2014) or 100 nM AllStars Negative
Control siRNA (both Qiagen) were transfected into HEK-
293 T seeded at 3 × 104 cells per well of a 96 well dish, using
Lipofectamine 2000 (Invitrogen). Cells were detached using
trypsin 48 h after transfection, washed and resuspended in 1%
(w/v) PBS/BSA. Samples were analysed using an
LSRFortessa High Throughput Sampler (BD Biosciences).
Forward scatter and side scatter were used to gate live cells.
A mock transfected cell population was used as a negative
control. Data were analysed using FlowJo v10.0.6. Median
fluorescence intensity (MFI) was used as a measure of expres-
sion. 7500 GFP-positive cells were counted with n = 14 for
each condition.
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Western blotting
One hundred ng plasmid DNA and 100 nM miRNA mim-
ic (Nightingale et al. 2014) or 100 nM AllStars Negative
Control siRNA (both Qiagen) were transfected using
Lipofectamine 2000, into 2 × 105 HEK-293 T cells per
well of a 12 well dish. Samples were harvested in
Laemmli Buffer (Bio-Rad, UK) and boiled for 5 min at
95 °C before separation by SDS-PAGE using 4–20%
Mini-PROTEAN® TGX™ Gels (Bio-Rad). Membranes
were probed with either rabbit anti-Ov2 antibody (synthe-
sised using peptides RRSTNRRASRNFKKRLQEH (ami-
no acids 26–45, access ion # AY839756.1) and
EKKKEEIRRLQYWLSTHNC, (amino acids 67–85 ac-
cession # AY839756.1) peptides by Dundee Cell
Products, UK) or a mouse anti-beta Actin (mAbcam
8226) and appropriate fluorescent secondary antibodies
(LI-COR). Primary (1:1000) and Secondary antibodies
(1:10000) were diluted in PBS-T (PBS + 0.1% Tween
20 v/v). Protein bands were visualised using an Odyssey
CLx (LI-COR) and quantified using Image Studio Lite
version 3.1 (LI-COR). For each sample, the levels of
Ov2 were quantified and normalised to the level of actin.
Test ovhv2-miRNA samples were then compared to the
negative control siRNA. A total of three independent
western blots were performed with duplicates for each
condition.
Statistical analysis
Statistical analysis was performed using Minitab 17 software.
Differences between groups were analysed using a general
linear model followed by Tukey’s post-hoc test. P-values rep-
resent results from the post-hoc test.
Illustrations
Illustrations were generated using GraphPad Prism.
Results
Control of Ov2 expression by OvHV-2 encoded
miRNAs
The capacity of two OvHV-2-encoded miRNAs (ovhv2-miR-
17-10 (minimum free energy, mfe = −23.8 kcal/mol) and
ovhv2-miR-61-1 (mfe = −30.7 kcal/mol), Fig. 1), to affect
Ov2 expression was investigated .
HEK-293 T cells were transfected with Ov2-EGFPN1 and
either ovhv2-miR-17-10 mimic, ovhv2-miR-61-1 mimic, a
mixture of both or a negative control siRNA. Forty-eight
hours post transfection GFP expression was analysed by flowTa
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cytometry as described above. Overall, the percentage of GFP
positive cells was found to remain consistent between repli-
cates and conditions (data not shown). To control for off-target
effects, the ability of the OvHV-2 miRNA mimics to reduce
expression of GFP alone was also examined. No significant
changes in the MFI were observed when ovhv2-miR-17-10 or
a combination of both ovhv2-miRs were co-transfected with
an EGFPN1 construct compared to a negative control siRNA
(Fig. 2). A decrease of 25% (p ≤ 0.01) in the MFI was ob-
served when ovhv2-miR-61-1 was co-transfected with an
EGFPN1 construct compared to the negative control siRNA
(Fig. 2). Significant decreases (p ≤ 0.0001 for all) of 35%,
39% and 44% in the MFI were observed when ovhv2-miR-
17-10, ovhv2-miR-61-1 or a combination of both ovhv2-miRs
respectively were co-transfected with an Ov2- EGFPN1 con-
struct compared to a negative control siRNA (Fig. 2).
As there were potential off target effects of the ovhv2-miR-
61-1 on EGFP we investigated the effects of the OvHv-2
miRNAmimics to regulate expression of an untagged version
of Ov2, by western blot analysis using an Ov2 specific anti-
body. Using this approach, the ability of either ovhv2-miR-17-
10 or the ovhv2-miR-61-1 to reduce expression of Ov2 tran-
scripts that had either a disrupted ovhv2-miR-17-10 or ovhv2-
miR-61-1 binding site was also examined. In each case the
OvHV-2 mir 17-10
OvHV-2 mir 61-1
- - +  +  +  +  - -
- - - - + + + +
+   +    - - - - - - Scramble miRNA
Ov2 mut miR-17-10 
Actin
Ov2 mut miR 61-1
Actin
Actin
Ov2 
b
d
c
a
Fig. 3 Analysis of miRNAs targeting Ov2 by western blotting. HEK-
293 T were transfected with the expression construct Ov2-pcDNA3.1+
and the appropriate miRNA mimic or a scramble siRNA. Representative
western blots of protein extracts from cells transfected with (a) Ov2-
pcDNA3.1+, (b) mutated Ov2-mut -mIR-17-10 or (c) Ov2-mut-miR-
61-1 with ovhv2-mIR-17-10, ovhv2-miR-61-1 or a combination of both
are shown. (d) Ov2 was detected using an anti-Ov2 antisera and quanti-
fied using the LI-COR system. Expression of Ov2 was normalised to
expression of actin for each sample. Levels of expression in the presence
of test ovhv2-miRs were compared to a scrambled siRNA. * = p ≤ 0.05,
** = p ≤ 0.01, *** = p ≤ 0.0001
Fig. 2 Confirmation ofOv2 targeting bymiRNAsusingFlowcytometry.
293 T cells were co-transfected with either an EGFPN1 or an Ov2-EGFPN1
construct and ovhv2-miR-17-10, ovhv2-miR-61-1, a combination of both
ovhv2-miRs or a scrambled siRNA. The MFI for each sample was deter-
mined 48 h later by flow cytometry and test ovhv2-miRNAs were compared
to a scrambled siRNA control. ** = p ≤ 0.01, *** = p ≤ 0.0001. Error bars
show ±SEM. MFI =Mean Fluorescence Intensity
ovhv2-miR-17-10 binding site: 
mutated ovhv2-miR-17-10 binding site: 
b 
ovhv2-miR-61-1 binding site: 
mutated ovhv2-miR-61-1 binding site: 
a 
Fig. 1 RNAHybrid analysis showing predicted binding of ovhv2-
miR- 61-1 and ovhv2-miR- 17-10 to Ov2 target sequence.
RNAHybrid analysis showing predicted binding, with minimum free
energys (mfe) of ovhv2-miR- 61-1(a) and ovhv2-miR- 17-10 (b) to the
Ov2 target sequence. The RNAHybrid analysis showing predicted bind-
ing ovhv2-miR-61-1 (a) and ovhv2-miR-17-10 (b) to a mutated Ov2
target sequence is shown underneath. Constraints on miRNA binding
included perfect complementarity between nucleotides 2 and 8 and no
G:U pairing within this region
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mutagenesis was designed to mutate the binding site, without
impacting on the coding sequence of Ov2 (Fig. 1).
When either ovhv2-miR-17-10 or ovhv2-miR-61-1 were
co-transfected with an Ov2- pcDNA3.1(+) construct signifi-
cant reductions of approximately 40% (p ≤ 0.05 for both
ovhv2-miRNAs) were observed compared to the negative
control siRNA. A reduction of approximately 60% was ob-
served compared to the negative control siRNA when both
ovhv2-miR-17-10 and ovhv2-miR-61-1 were co-transfected
with the Ov2- pcDNA3.1(+) construct (p ≤ 0.01).
Restoration of expression of Ov2 was observed when
ovhv2-miR-61-1 was co-transfected with Ov2-mut-miR-61-
1 (p ≤ 0.58), though this construct remained sensitive to the
presence of ovhv2-miR-17-10 (p ≤ 0.05; Fig. 3). However,
restoration of Ov2 expression was not observed when Ov2-
mut-miR-17-10 was expressed in the presence of either
ovhv2-miR-17-10 or ovhv2-miR-61-1 (p ≤ 0.01; Fig. 3).
Discussion
Evidence is accumulating from a number of herpesvirus, includ-
ing HCMVand KSHV, that virally-encoded miRNAs may func-
tion like a rheostat, in fine-tuning the mechanism of reactivation
by targeting viral transactivators (Grey et al. 2007; Bellare and
Ganem 2009; Riaz et al. 2014). A similar role for miRNAs, in
increasing stringency to biological pathways, has also been pos-
tulated for cellular miRNAs (Ebert and Sharp 2012). In this
study, ovhv2-miR-17-10 and ovhv2-miR-61-1 have been shown
to target Ov2. Mutation of the target seed sequence of ovhv2-
miR-61-1 restored Ov2 expression levels to that of the control
confirming that the target site of ovhv2-miR-61-1, within the
coding sequence of the Ov2 mRNA, had been successfully iden-
tified. However, it was not possible to determine the functional
binding site of ovhv2-miR-17-10. It is known that functional
miRNAs can have G:U pairing within the seed sequence
(Didiano and Hobert 2006; Doench and Sharp 2004). To disrupt
ovhv2-miR-17-10 binding, three amino acids (an arginine, an
asparagine and a phenylalanine) were mutated. There are only
two codons available for asparagine (AAC and AAT) and phe-
nylalanine (TTC and TTT) and due to constraints of the genetic
code mutation of these two amino acids results in changes in the
base pairing of ovhv2-miR-17-10 with Ov2 from G:C to G:U.
G:U pairing is allowed in seed sequences and can still result in
functional knockdown of the target. Furthermore, RNAhybrid
(Rehmsmeier et al. 2004) analysis using ovhv2-miR-17-10,
allowing for G:U pairing and perfect complementarity between
the Ov2 coding sequence and the miRNA seed sequence, iden-
tified two further possible and non-overlapping sites for ovhv2-
miR-17-10 binding, in addition to the site tested. It is therefore
possible that the reason Ov2 expression could not be restored, by
mutation of the ovhv2-miR-17-10 binding site, is due both to the
presence of functionally redundant ovhv2-miR-17-10 binding
sites within the Ov2mRNA or that ovhv2-miR-17-10 is still able
to interact with the mutated Ov2 binding site via non-canonical
G:U pairing.
Amongst cellular mRNAs, it has been shown that those
that encode regulatory proteins, such as transcription factors,
have a short half-life (Sharova et al. 2009; Yang et al. 2003).
That Ov2 has a short half-life most likely explains the diffi-
culties faced in detecting Ov2 transcript, despite being able to
routinely detect protein and DNA in transfected cells. As a
result it remains unclear whether ovhv2-miR-17-10 and
ovhv2-miR-61-1 function to inhibit Ov2 expression via trans-
lational repression or transcriptional degradation. Previously,
we have reported that ovhv2-miR-17-10 targets the OvHV-2
RTA transcript (Riaz et al. 2014). The observation that Ov2 is
targeted by at least two viral-encodedmiRNAs indicates that it
has an important regulatory role in OvHV-2 biology. Using a
reporter assay system, we have been able to demonstrate that
Ov2 is capable of modulating RTA (See accompanying paper
Dry et al. 2019). We propose that OvHV-2 utilises miRNAs
ovhv2-miR-5 (Riaz et al. 2014), ovhv2-miR-17-10 and
ovhv2-miR-61-1 to post-transcriptionally maintain latency,
by restricting expression of RTA and Ov2, respectively, there-
by increasing stringency to the process of reactivation by
preventing precocious initiation of the productive lytic cycle.
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